Grit Biotechnology: Clinical Trials

30 trials sponsored by Grit Biotechnology, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 recruiting, 9 terminated, 2 not yet recruiting, 2 withdrawn. 11 Early Phase 1, 9 Not applicable, 9 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Early Phase 111Recruiting 6, Terminated 3, Not yet recruiting 2
Not applicable9Recruiting 4, Terminated 3, Withdrawn 2
Phase 19Recruiting 5, Terminated 3, Active not recruiting 1
Phase 24Recruiting 3, Terminated 1

Follow Grit Biotechnology: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy		Early Phase 1Not yet recruitingGrit Biotechnology302027-08-012026-09-11
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
GT737 Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML)		Early Phase 1Not yet recruitingGrit Biotechnology362027-05-012026-09-11
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
GT307 injection - Advanced Solid Tumors		Not applicableWithdrawnGrit Biotechnology2026-04-302026-06-09
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
GT729 Injection - cGVHD		Early Phase 1RecruitingGrit Biotechnology362025-12-182026-04-14
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
GT801 Injection - Moderate to Severe Refractory Autoimmune Disease		Early Phase 1RecruitingGrit Biotechnology222025-11-072026-05-27
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
GT201, IL-2, PD-1 inhibitor - Advanced Solid Tumors		Phase 1 / Phase 2RecruitingGrit Biotechnology782025-11-012026-08-19
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
GT719 Injection - Auto Immune Disease		Early Phase 1RecruitingGrit Biotechnology302025-10-282026-04-16
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
GT801 Injection - B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL)		Early Phase 1RecruitingGrit Biotechnology282025-09-262026-07-20
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
GT719 Injection - Autoimmune Diseases		Early Phase 1RecruitingGrit Biotechnology102025-08-222026-09-18
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
GT719 Injection - Hematological Malignancy (Leukemia- Lymphoma)		Phase 1 / Phase 2RecruitingGrit Biotechnology462025-04-182026-09-18
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
GT719 Injection - Hematological Malignancy (Leukemia- Lymphoma)		Early Phase 1RecruitingGrit Biotechnology342025-03-102025-12-30
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
GT719 Injection - Neurological Autoimmune Diseases		Phase 1RecruitingGrit Biotechnology302025-01-142026-09-11
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
IB-T101 injection - Advanced Clear Renal Cell Carcinoma, Adult		Phase 1RecruitingGrit Biotechnology122024-12-062026-04-14
Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma
GTE001 injection - Advanced Lung Adenocarcinoma；Adult		Phase 1TerminatedGrit Biotechnology22024-07-182026-04-23
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
GT201 injection - Adult, Lung Cancer		Not applicableTerminatedGrit Biotechnology22024-07-182026-04-27
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
GT307 injection - Adult		Not applicableRecruitingGrit Biotechnology182024-07-042026-04-14
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
GT307 injection - Adult		Not applicableRecruitingGrit Biotechnology182024-06-282026-04-14
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
GT201 in combination with PD-1 inhibitors - HNSCC		Not applicableRecruitingGrit Biotechnology322024-05-122026-04-24
Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours
GT307 injection - Solid Tumor, Adult		Not applicableRecruitingGrit Biotechnology182024-04-182026-01-26
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
GT101 injection, Gemcitabine injection - Adult		Phase 2RecruitingGrit Biotechnology832024-04-022026-04-15

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Hematologic Neoplasms (2)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Autoimmune Diseases (1)  ·  Burkitt Lymphoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Glomerulonephritis, IGA (1)  ·  Glomerulonephritis, Membranous (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Interventions

Immune Checkpoint Inhibitors (2)  ·  Gemcitabine (1)  ·  Interleukin-2 (1)  ·  Toll-Like Receptor 1 (1)  ·  dimethyl-2-(tetrahydro-2-furanyl)ethylsulfonium (1)

Countries

China (28)

Top investigators

Chuan Qin (1)  ·  Daishi Tian (1)  ·  Wei Wang (1)